Browse - MDPD

1. Disease wise BioProjects

foo

2. Biome wise BioProjects

(Please click on the biome names in figure to get details)

3. Disease subgroup wise BioProjects

Acute Respiratory Distress Syndrome (ARDS)	ARDS; ARDS Hospital Death
Asthma	Asthma; Asthma Baseline; Asthma Exacerbation; Asthma ICU; Asthma MCU; Asthma No Exacerbation; Asthma Recovery; Atopic Asthma; Bacterial Eosinophilic Asthma; Bacterial Non Eosinophilic Asthma; Eosinophilic Asthma; Fungi Eosinophilic Asthma; Fungi Non Eosinophilic Asthma; Mild/Moderate School-age Asthma; Non Eosinophilic Asthma; School Asthma; Severe Asthma; Severe School-age Asthma
Asthma-COPD Overlap (ACO)	Asthma-COPD Overlap (ACO)
Bronchiectasis	Bronchiectasis; Bronchiectasis Exacerbation-After Treatment; Bronchiectasis Exacerbation-Before Treatment; Bronchiectasis Exacerbation-End of Treatment; Bronchiectasis Exacerbation-Post Treatment When Stable; Bronchiectasis Exacerbation-Start of Treatment; Bronchiectasis Stable; Bronchiectasis-Allergic Bronchopulmonary Aspergillosis (ABPA); Bronchiectasis-Idiopathic; Bronchiectasis-Immunodeficiency; Bronchiectasis-Other; Bronchiectasis-Post Infection; Bronchiectasis-Primary Ciliary Dyskinesia (PCD); Non Cystic Fibrosis Bronchiectasis
Bronchiolitis	Bronchiolitis Moderate; Bronchiolitis Severe
Bronchitis	Persistent Bacterial Bronchitis; Protracted Bacterial Bronchitis
Chronic Obstructive Pulmonary Disease (COPD)	Bacterial Eosinophilic COPD; Bacterial Non Eosinophilic COPD; Biomass Exoposure COPD; COPD; COPD 0 Months; COPD 11 Months; COPD 3 Months; COPD 5 Months; COPD 6 Months; COPD 7 Months; COPD 9 Months; COPD Day 1 Sample; COPD Day 14 Sample; COPD Day 7 Sample; COPD End of Exacerbation; COPD Exacerbation; COPD Follow Up; COPD Frequent Exacerberator; COPD GOLD 1; COPD GOLD 2; COPD GOLD 3; COPD GOLD 4; COPD Infrequent Exacerberator; COPD Long Term Inhaled Corticosteroids; COPD Non Survivor; COPD Patient 1; COPD Patient 10; COPD Patient 12; COPD Patient 3; COPD Patient 5; COPD Patient 6; COPD Patient 7; COPD Post Therapy; COPD Pulmonary Intervention; COPD Recovery; COPD Severe; COPD Short Term Inhaled Corticosteroids; COPD Six Months from First Stable Visit; COPD Six Week Post Exacerbation; COPD Stable; COPD Start of Exacerbation; COPD Survivor; COPD Two Week Post Exacerbation; COPD with Bronchitis; COPD with Periodontitis; Eosinophilic COPD; Fungi Eosinophilic COPD; Fungi Non Eosinophilic COPD; Non Eosinophilic COPD; Tobacco Smoke Exopsure COPD
Control	Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV); Breast Cancer; Control; Control Group After 4 Treatment Cycles; Control Group Before Treatment; COVID-19 Negative; COVID-19 Never Positive; COVID-19 SARS-CoV-2 Negative; COVID-19 Uninfected; Family Control; H1N1 Patient; Human Immunodeficiency Virus (HIV); Intensive Care Unit Patients (ICU); Lung Abscess; Lymphangioleiomyomatosis (LAM); Mild/Moderate Pre-school Wheeze; No Tumor Side BALF; Nodules Adjacent Tissue; Non ARDS; Non Asthma; Non Atopic Asthma; Non Cancer; Non Cancer Control; Non COPD; Non COVID-19; Non COVID-19 ICU; Non Cystic Fibrosis; Non Cystic Fibrosis LowCF; Non Cystic Fibrosis MedCF; Non Cystic Fibrosis MiPro; Non Diseased; Non Hospital Acquired Pneumonia (HAP), Non ARDS; Non Lower Respiratory Tract Infections (LRTI); Non Pneumocystis Pneumonia; Non Pneumonia; Non Smoker; Non Tuberculosis; Non Ventilator Associated Pneumonia(VAP); Normal Lung Tissue; Periodontitis; Pneumonia Negative; Preschool Control; Preschool Wheeze; Rheumatoid Arthritis; Severe Pre-school Wheeze; Tracheomalacia; Tuberculosis Negative; Wheeze Exacerbation
COPD-Bronchiectasis Association (CBA)	COPD-Bronchiectasis Association (CBA)
COVID-19	COVID-19; COVID-19 0 Months; COVID-19 1 Months; COVID-19 4 Weeks After SARS-CoV-2 Infection; COVID-19 6 Months; COVID-19 8 Weeks After SARS-CoV-2 Infection; COVID-19 9 Months; COVID-19 Acute; COVID-19 Ambulatory; COVID-19 Asymptomatic; COVID-19 Asymptomatic Adult; COVID-19 Asymptomatic Early Phase; COVID-19 Asymptomatic Recovery Phase; COVID-19 Asymptomic/Mild; COVID-19 Children; COVID-19 Convalescence; COVID-19 Coronary Care Unit (CCU) Workers; COVID-19 Critical; COVID-19 Deceased; COVID-19 Discharged; COVID-19 Early Infection (1st-2nd Trimester); COVID-19 High Intensity; COVID-19 Indeterminate; COVID-19 Inpatient; COVID-19 Inpatient No Antibiotics; COVID-19 Intensive Care Unit (ICU) Workers; COVID-19 Late Infection (3rd Trimester); COVID-19 Low Intensity; COVID-19 Medium; COVID-19 Mild; COVID-19 Moderate; COVID-19 Non Critical; COVID-19 Non Severe; COVID-19 Omicron Variant; COVID-19 Operating Room (OR) Workers; COVID-19 Original Strain; COVID-19 Outpatient; COVID-19 Paucisymptomatic; COVID-19 Postconvalescence; COVID-19 Recovery; COVID-19 Respiratory Medicine Workers; COVID-19 SARS-CoV-2 Positive; COVID-19 Severe; COVID-19 Severe with Admission to ICU; COVID-19 Severe with Hospitalization; COVID-19 Severe/Critical; COVID-19 Severely Symptomatic; COVID-19 Symptomatic; COVID-19 with Breast Cancer; Long COVID-19; Mechanically Ventilated COVID-19
Cystic Fibrosis	Cystic Fibrosis; Cystic Fibrosis Additional Symptoms of Airway Complications; Cystic Fibrosis After Antibiotics; Cystic Fibrosis Baseline; Cystic Fibrosis Before Antibiotics; Cystic Fibrosis Exacerbation; Cystic Fibrosis Exacerbation (No Treatment); Cystic Fibrosis Exacerbation (Treatment with Antibiotics); Cystic Fibrosis Follow Up; Cystic Fibrosis Inter Antibacterial Therapy; Cystic Fibrosis LowCF; Cystic Fibrosis MedCF; Cystic Fibrosis Mild; Cystic Fibrosis MiPro; Cystic Fibrosis Moderate; Cystic Fibrosis No Exacerbation; Cystic Fibrosis On Antibiotics No Exacerbation; Cystic Fibrosis Post Antibacterial Therapy; Cystic Fibrosis Pre Antibacterial Therapy; Cystic Fibrosis Recovery (within 1 Month After Stopping Antibiotics for Exacerbation); Cystic Fibrosis Severe; Cystic Fibrosis Treatment
Healthy	Healthy; Healthy Adult; Healthy Children; Healthy Former Smoker; Healthy Non Smoker; Healthy Smoker
Idiopathic Pulmonary Fibrosis (IPF)	IPF; IPF After 6 Months; IPF Baseline
Interstitial Lung Disease (ILD)	Connective Tissue Disease Associated ILD (CTD-ILD); ILD; ILD Exacerbation
Lung Cancer	Adenocarcinoma; Adenocarcinoma I; Adenocarcinoma II; Adenocarcinoma III; Adenocarcinoma IV; Adenocarcinoma, Squamous Celll Carcinoma II; Adenocarcinoma: BAC features; Adenocarcinoma: Mixed Features; Adenosquamous Carcinoma; Benign Lung Tumor Tissue; Bronchioalveolar Carcinoma; Inflammation Nodule Lung Tissue; Large Cell Carcinoma; Large Cell Carcinoma III; Large Cell Carcinoma IV; Lung Cancer; Lung Cancer JK5G Group After 4 Treatment Cycles; Lung Cancer JK5G Group Before Treatment; Lung Tumor Tissue; Mixed; Non Small Cell Lung Cancer (NSCLC); Non Small Cell Lung Cancer (NSCLC) I; Non Small Cell Lung Cancer (NSCLC) III; Non Small Cell Lung Cancer (NSCLC) IV; Non Small Cell Lung Cancer (NSCLC) Non Responsive Pre Treatment; Non Small Cell Lung Cancer (NSCLC) Non Resposive Post Treatment; Non Small Cell Lung Cancer (NSCLC) Progression Free Survival Above 6 Months; Non Small Cell Lung Cancer (NSCLC) Progression Free Survival Below 6 Months; Non Small Cell Lung Cancer (NSCLC) Responsive Post Treatment; Non Small Cell Lung Cancer (NSCLC) Responsive Pre Treatment; Poorly Differentiated Carcinoma IV; Small Cell Carcinoma; Small Cell Carcinoma III; Small Cell Lung Cancer (SCLC); Squamous Cell Carcinoma; Squamous Cell Carcinoma I; Squamous Cell Carcinoma II; Squamous Cell carcinoma III; Squamous Cell Carcinoma IV; Tumor Adjacent Tissue; Tumor Side BALF
Other Pulmonary Infections	Acute Respiratory Infection; Bacterial Infection; COVID-19 Associated Pulmonary Aspergillosis; Fungal Infection; Influenza Associated Pulmonary Aspergillosis; Influenza Virus Infection; Lower Respiratory Tract Infections (LRTI); Metapneumovirus Infection; Respiratory Infections; Respiratory Syncytial Virus (RSV) Infection; Rhinovirus Infection; Unknown Lower Respiratory Tract Infections (LRTI)
Pneumonia	Adenoviral Pneumonia; Aspiration Pneumonia; C. psittaci Pneumonia; Community Acquired Pneumonia (CAP); Culture Negative Pneumonia; Culture Positive Pneumonia; Hospital Acquired Pneumonia (HAP); Hospital Acquired Pneumonia (HAP), ARDS; M. pneumoniaePneumonia; Pediatric Pneumonia; Pneumocystis Pneumonia; Pneumonia; Pneumonia Indeterminate; Post Treatment M. pneumoniae Pneumonia; Pre Treatment M. pneumoniae Pneumonia; S. PneumoniaePneumonia; Ventilator Associated Pneumonia(VAP)
Pneumonitis	Checkpoint Inhibitor Pneumonitis(CIP); Chronic Hypersensitivity Pneumonitis (CHP)
Pulmonary Hypertension	Chronic Thromboembolic Pulmonary Hypertension (CTEPH); Pulmonary Arterial Hypertension (PAH); Pulmonary Hypertension
Sarcoidosis	Sarcoidosis
Tuberculosis	Cured Tuberculosis Group; Drug Sensitive Tuberculosis; Drug Sensitive Tuberculosis After 6 Month Treatment; Month Treatment Tuberculosis; Multi Drug Resistant Tuberculosis; Multidrug Resistant Tuberculosis After 6 Month Treatment; Mycobacterium africanum; Mycobacterium tuberculosis; Nontuberculous Mycobacteria (NTM); Treated Tuberculosis Group; Tuberculosis; Tuberculosis Latently Infected; Tuberculosis Positive; Untreated Tuberculosis Group; Week Treatment Tuberculosis; Zero Day Tuberculosis

foo